United Total Stockholder Equity vs Accounts Payable Analysis
UTHR Stock | USD 274.67 0.41 0.15% |
United Therapeutics financial indicator trend analysis is much more than just breaking down United Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether United Therapeutics is a good investment. Please check the relationship between United Therapeutics Total Stockholder Equity and its Accounts Payable accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.
Total Stockholder Equity vs Accounts Payable
Total Stockholder Equity vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of United Therapeutics Total Stockholder Equity account and Accounts Payable. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between United Therapeutics' Total Stockholder Equity and Accounts Payable is -0.22. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of United Therapeutics, assuming nothing else is changed. The correlation between historical values of United Therapeutics' Total Stockholder Equity and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of United Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Stockholder Equity i.e., United Therapeutics' Total Stockholder Equity and Accounts Payable go up and down completely randomly.
Correlation Coefficient | -0.22 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Accounts Payable
An accounting item on the balance sheet that represents United Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of United Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from United Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into United Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.As of 05/21/2024, Enterprise Value is likely to grow to about 11.8 B, while Selling General Administrative is likely to drop slightly above 207.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.6B | 1.8B | 2.1B | 2.2B | Total Revenue | 1.7B | 1.9B | 2.3B | 2.4B |
United Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
United Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
United Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.9B | 4.6B | 5.2B | 6.0B | 7.2B | 7.5B | |
Other Current Liab | 39.6M | 319.2M | 301.6M | 339.1M | 71M | 116.3M | |
Total Current Liabilities | 463M | 323.3M | 305.4M | 343.2M | 804.4M | 844.6M | |
Total Stockholder Equity | 2.8B | 3.4B | 4.0B | 4.8B | 6.0B | 6.3B | |
Property Plant And Equipment Net | 738.5M | 731.6M | 780.9M | 861.5M | 1.0B | 1.1B | |
Net Debt | 111.6M | 61.3M | (94.8M) | (161.2M) | (507.7M) | (482.3M) | |
Retained Earnings | 3.3B | 3.8B | 4.3B | 5.0B | 6.0B | 6.3B | |
Accounts Payable | 23.1M | 9.9M | 4.1M | 3.8M | 5.6M | 10.2M | |
Cash | 738.4M | 738.7M | 894.8M | 961.2M | 1.2B | 1.3B | |
Non Current Assets Total | 2.0B | 2.4B | 2.8B | 2.7B | 3.6B | 3.8B | |
Non Currrent Assets Other | 154.6M | 169.9M | 108.2M | 114.3M | 151.8M | 91.5M | |
Cash And Short Term Investments | 2.3B | 3.0B | 3.6B | 4.2B | 3.0B | 3.1B | |
Net Receivables | 151.4M | 157.4M | 198.7M | 220.4M | 278.9M | 292.8M | |
Common Stock Shares Outstanding | 43.8M | 44.6M | 47.3M | 48.5M | 49.7M | 50.7M | |
Liabilities And Stockholders Equity | 3.9B | 4.6B | 5.2B | 6.0B | 7.2B | 7.5B | |
Non Current Liabilities Total | 670M | 896.5M | 904.8M | 904.6M | 377.8M | 269.4M | |
Other Current Assets | 133.8M | 88.3M | 100.4M | 219.2M | 166.2M | 174.5M | |
Other Stockholder Equity | (531.3M) | (430.5M) | (333.8M) | (190.8M) | (30.2M) | (28.7M) | |
Total Liab | 1.1B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | |
Total Current Assets | 1.9B | 2.2B | 2.3B | 3.4B | 3.6B | 3.7B | |
Short Term Investments | 747.5M | 1.1B | 1.0B | 1.9B | 1.8B | 1.9B | |
Property Plant And Equipment Gross | 738.5M | 731M | 1.1B | 1.2B | 1.5B | 1.5B | |
Intangible Assets | 130.3M | 130.1M | 16.6M | 16.5M | 80.5M | 84.5M | |
Other Liab | 67M | 79.4M | 104.8M | 76.8M | 88.3M | 60.5M | |
Other Assets | 293.8M | 1.6B | 370.1M | 413.5M | 475.5M | 284.7M | |
Inventory | 93.4M | 86.5M | 93.8M | 102M | 111.8M | 55.9M | |
Property Plant Equipment | 738.5M | 731.6M | 780.9M | 861.5M | 990.7M | 1.0B | |
Net Tangible Assets | 2.6B | 3.2B | 3.9B | 4.8B | 5.5B | 5.7B | |
Retained Earnings Total Equity | 3.3B | 3.8B | 4.3B | 5.0B | 5.8B | 6.1B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.27 | Earnings Share 21.12 | Revenue Per Share 53.184 | Quarterly Revenue Growth 0.337 | Return On Assets 0.1225 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.